The AHA filed an amicus brief Oct. 4 in the U.S. Court of Appeals for the 5th Circuit challenging a decision by the U.S. District Court for the Northern District of Texas, which ruled that independent dispute resolution awards under the No Surprises Act are judicially unenforceable. The AHA argued the district court's decision was inconsistent with longstanding interpretations of the law and would threaten serious harm to providers. 
 
"[T]he district court interpreted the NSA to render entire sections of it nugatory," AHA wrote. "There is no need for an IDR process — or any of the NSA’s other payment mechanisms — if nothing requires insurers to render payment upon an IDR determination." The district court’s interpretation of the No Surprises Act “gives insurers significant leverage to demand confiscatory discounts from out-of-network providers, as well as to exact across-the-board rate cuts from in-network providers… Both in- and out-of-network providers will thus find themselves perpetually underpaid or even uncompensated for their valuable services, and patients will lose providers and critical care as a result,” the brief notes. 

The American Medical Association, Federation of American Hospitals and the Texas Medical Association joined AHA in the brief.

Related News Articles

Headline
The AHA, 340B Health, the Minnesota Hospital Association and American Society of Health-system Pharmacists Oct. 4 filed an amicus brief in the U.S. District…
Headline
A Louisiana district court Sept. 30 upheld a state law prohibiting drug companies from denying Louisiana hospitals 340B discounts for drugs dispensed at…
Headline
The AHA Sept. 9 released a report highlighting how hospitals’ arrangements with community and specialty pharmacies improve access to care for underserved…
Headline
A district court in Baltimore Sept. 5 ruled against drug companies and PhRMA, denying their attempt to obtain a preliminary injunction against 340B pricing for…
Headline
The AHA, 340B Health and the American Society of Health-System Pharmacists last week filed an amicus brief in a federal district court in Missouri, defending…
Headline
If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the…